EIT Pharma Secures $35 Million in Latest Series A Funding Round

EIT Pharma secured $35 million in its latest Series A, adding another data point to the Industrials & Manufacturing funding market.

EIT Pharma Raises $35 million in Funding

EIT Pharma Closes Oversubscribed $35 Million Series A Round, Led by Propel Bio Partners. "This oversubscription of this round is a validation of EIT Pharma's founding belief that advancing important medicines is about recognizing unrealized potential and assembling the scientific, clinical, regulatory, and commercial expertise to turn that potential into a treatment for patients," said Dr. Leen Kawas, PhD, Chief Executive Officer of EIT Pharma.

Investors Behind the Funding

The round was backed by Propel Bio Partners. Capvizr tracks this investor activity alongside sector momentum, co-investor patterns, and recent comparable raises.

Company Profile and Market Context

EIT Pharma operates in Industrials & Manufacturing. EIT Pharma's financing adds to recent private-market activity.

Strategic Use of Funds

Lonafarnib, and future manufacturing and commercial readiness steps for lonafarnib, subject to regulatory approval.

Looking Ahead

said Dr. Leen Kawas, PhD, Chief Executive Officer of EIT Pharma.

Source reference: original announcement/article.